Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Objectives:
1. To determine if dose intensive Vincristine, Doxorubicin, Cyclophosphamide and
Dexrazoxane (VACdxr) with or without ImmTherTM can improve the 2-year disease-free
survival seen with standard VAC therapy.
2. To evaluate the feasibility and describe the toxicity associated with VACdxr.
3. To evaluate the feasibility and describe the toxicity of administering ImmTherTM on a
weekly basis for 50- 52 weeks.
4. To determine which therapy (VACdxr+ or VACdxr-) is worthy of further evaluation.